Paul Vigano Sells 2,250,000 Shares of Aveanna Healthcare (NASDAQ:AVAH) Stock

Posted by George Bondi on Aug 26th, 2026

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH – Get Free Report) major shareholder Paul Vigano sold 2,250,000 shares of the company’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $11.50, for a total transaction of $25,875,000.00. Following the completion of the transaction, the insider owned 12,315,892 shares in the company, valued at approximately $141,632,758. This represents a 15.45% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Aveanna Healthcare Stock Down 0.8%

AVAH stock opened at $13.59 on Wednesday. The company has a 50 day moving average of $9.83 and a two-hundred day moving average of $7.99. The company has a market cap of $2.97 billion, a price-to-earnings ratio of 11.05, a PEG ratio of 0.96 and a beta of 1.90. Aveanna Healthcare Holdings Inc. has a 12-month low of $5.93 and a 12-month high of $13.98. The company has a quick ratio of 1.16, a current ratio of 1.16 and a debt-to-equity ratio of 4.47.

Aveanna Healthcare (NASDAQ:AVAH – Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported $0.22 EPS for the quarter, beating the consensus estimate of $0.17 by $0.05. Aveanna Healthcare had a net margin of 10.56% and a return on equity of 80.70%. The business had revenue of $670.48 million for the quarter, compared to analysts’ expectations of $638.61 million. On average, equities analysts anticipate that Aveanna Healthcare Holdings Inc. will post 0.68 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on AVAH shares. BMO Capital Markets upped their target price on Aveanna Healthcare from $10.00 to $14.00 and gave the stock an “outperform” rating in a research report on Friday, August 14th. Wall Street Zen cut Aveanna Healthcare from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 15th. Stephens upgraded Aveanna Healthcare from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $10.00 to $11.00 in a report on Friday, May 15th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Aveanna Healthcare in a research report on Thursday, July 2nd. Finally, UBS Group lifted their target price on shares of Aveanna Healthcare from $8.00 to $13.00 and gave the company a “neutral” rating in a research note on Friday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and five have given a Hold rating to the company. According to MarketBeat, Aveanna Healthcare has an average rating of “Moderate Buy” and a consensus target price of $12.89.

Check Out Our Latest Stock Report on Aveanna Healthcare

Trending Headlines about Aveanna Healthcare

Here are the key news stories impacting Aveanna Healthcare this week:

Positive Sentiment: Royal Bank of Canada raised its price target to $16 from $10 and upgraded AVAH to “outperform.” The upgrade reinforces the bullish outlook following the stock’s recent rally. Benzinga analyst coverage
Positive Sentiment: Truist Financial increased its price target to $15 from $11, although it maintained a “hold” rating. Other analysts have also raised targets after Aveanna exceeded quarterly earnings and revenue expectations. Benzinga analyst coverage
Positive Sentiment: Aveanna reported quarterly EPS of $0.22 versus the $0.17 consensus estimate and revenue of $670.48 million versus expectations of $638.61 million. The earnings beat supports the improved analyst outlook and investor interest in the shares.
Neutral Sentiment: Management will participate in the Jefferies Healthcare Services and Technology Conference on September 15. The presentation and one-on-one investor meetings could provide additional business updates, but the event is not an immediate financial catalyst. Aveanna conference announcement
Negative Sentiment: Major shareholders, including Bain Capital- and J.H. Whitney-affiliated holders, disclosed substantial sales in a roughly $176 million offering. Additional sales by CEO Jeff Shaner, director Rodney Windley, and insider Edwin Reisz at $11.50 per share could weigh on sentiment and increase concerns about selling pressure, even though these holders retained sizable positions. Home Health Care News offering report

Institutional Trading of Aveanna Healthcare

Institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in shares of Aveanna Healthcare by 38.0% during the 4th quarter. Vanguard Group Inc. now owns 5,577,010 shares of the company’s stock worth $45,564,000 after acquiring an additional 1,535,351 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Aveanna Healthcare by 49.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,334,374 shares of the company’s stock valued at $8,593,000 after acquiring an additional 441,707 shares in the last quarter. Segall Bryant & Hamill LLC raised its stake in shares of Aveanna Healthcare by 425.8% in the 1st quarter. Segall Bryant & Hamill LLC now owns 163,966 shares of the company’s stock valued at $1,056,000 after acquiring an additional 132,779 shares in the last quarter. NFJ Investment Group LLC acquired a new stake in Aveanna Healthcare in the 2nd quarter worth approximately $2,682,000. Finally, Weiss Asset Management LP acquired a new stake in Aveanna Healthcare in the 1st quarter worth approximately $732,000. Institutional investors and hedge funds own 87.96% of the company’s stock.

About Aveanna Healthcare

(Get Free Report)

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.